Cargando…
Tocilizumab and Baricitinib for Recovery From Acute Exacerbation of Combined Pulmonary Fibrosis and Emphysema Secondary to COVID-19 Infection: A Case Report
Pneumonia secondary to coronavirus disease 2019 (COVID-19) is exacerbated by a disproportionate increase in the systemic inflammatory response and cytokine storm due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Herein, we report the successful treatment of severe COVID-...
Autores principales: | Kai, Yoshiro, Matsuda, Masayuki, Suzuki, Kentaro, Kasamatsu, Takehito, Kajita, Akihiro, Uno, Kenji, Muro, Shigeo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033509/ https://www.ncbi.nlm.nih.gov/pubmed/35481309 http://dx.doi.org/10.7759/cureus.23411 |
Ejemplares similares
-
Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab
por: Kai, Yoshiro, et al.
Publicado: (2022) -
Pneumomediastinum and Subcutaneous Emphysema in an Adult Male From Nepal Infected With COVID-19
por: Kafle, Satyasuna, et al.
Publicado: (2021) -
Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan
por: Hassan, Muhammad, et al.
Publicado: (2021) -
Prevalence of Hospital-Acquired Pneumonia Among Patients With Severe to Critical COVID-19 Pneumonia Given Tocilizumab
por: Adre, Lorenzo Abednego B, et al.
Publicado: (2023) -
Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19
por: Skarbinski, Jacek, et al.
Publicado: (2022)